Entecavir in decompensated HBV cirrhosis: The future is looking brighter

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 147-149

  Fontana, Robert J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; MORTALITY; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 75449102162     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.025     Document Type: Editorial

References (26)

1. Lok A.S.F., and McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 50 (2009) 1-36
2. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50 (2009) 227-242
3. Shamliyan T.A., MacDonald R., Shaukat A., Taylor B.C., Yuan J.M., Johnson J.R., et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 150 (2009) 111-124
4. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
5. Fontana R.J. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 23 (2003) 89-100
6. Fontana R.J., Hann H.W., Perrillo R.P., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
7. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38 (2003) 1419-1427
8. Schiff E.R., Lai C.L., Hadziyanis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transplant 13 (2007) 349-360
9. Hadziyannis S., Tassopoulos N., Heathcote E., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1741-1751
10. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 (2005) 804-817
11. Chang T.T., Gish R.G., De Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
12. Leung N., Peng C.Y., Hann H.W., et al. Early hepatitis B virus DNA reduction in hepatitis B e-antigen positive patients with chronic hepatitis B: a randomized, international study of entecavir versus adefovir. Hepatology 49 (2009) 72-79
13. Tenney D.J., Rose R.E., Baldick C.J., Pokornowski K.A., Eggers B.J., Fang J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 49 (2009) 1503-1514
14. Marcellin P., Buti M., Krastev Z., et al. Tenoofivir disporixl fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008) 2442-2455
15. Smow-Lampart A., Chappell B.J., Curtis M., Zhu Y., Heatthcote E.J., Marcellin G.P., et al. Resistance surveillance for up to 144 weeks in HBeAg+ and HBeAg- patients treated with tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase. Hepatology 50 (2009) 532A [Abstract]
16. Shim J.H., Lee H.C., Kim K.M., Lim Y.S., Chung Y.H., Lee Y.S., et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 52 (2010) 176-182
17. Mazzucco E.C., Hamatake R.K., Colonno R.J., and Tenney D.J. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 52 (2008) 598-605
18. Fontana R.J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49 5 Suppl. (2009) S185-S195
19. Lange C.M., Bojunga J., Hofmann W.P., Wunder K., Mihm U., Zeuzem S., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) [e-pub]
20. Kim B.K., Oh J., Kwon B.K., Choe W.H., Ko S.Y., Rhee K.H., et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 51 (2009) 829-834
21. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., Sarin S.K., Tanwandee T., Leung N., et al. Efficacy, safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 50 (2009) 505A [Abstract]
22. Pellicelli A.M., Barbarini G., Romano M., Furlan C., Paffetti A., Villani R., et al. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral, biochemical outcomes at one year. Hepatology 50 (2009) 514A [Abstract]
23. Schiff E.R., Liaw Y., Lee C., Akarc U.S., George P.V., Wong F., et al. Interim results of a double-blind, randomized phase 2 study of the safety of tenofovir disoproxil fumarate, emtricitabine plus tenofovir disoproxil fumarate, entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease. Hepatology 50 (2009) 222 [Abstract]
24. Gallant J., Staszewski E.S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al. Efficacy and safety of tenofovir DV vs. stavudine in combination therapy in anti-retroviral naïve patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
25. Raijnders J.G., Vries-Sluijs T., Hansen B.E., Zaaijer H.L., Prins J.M., Schuttten M., et al. Five-year tenofovir therapy is associated with maintained virologic response but significant decline in renal function in HIV-HBV coinfected patients. Hepatology 50 (2009) 506A [Abstract]
26. Constable C., Childs K., Bachon M.L., Carriero D.C., Mullen M.P., Dieterich D.T., et al. Does tenofovir increase the risk of abnormal bone and calcium metabolism?. Hepatology 51 (2009) 518A [Abstract]